Cardiac Resynchronization Therapy (CRT) Devices Market

Germany implanted 261.4 cardiac resynchronization devices per million people in 2023, while middle-income countries reported just 13.4 per million in 2024, according to the ESC Atlas of Cardiology; that gap of nearly 20 times is the whole growth story. The cardiac resynchronization therapy (CRT) devices market covers implanted CRT defibrillators (CRT-D) and CRT pacemakers (CRT-P), sold as generator-plus-lead systems for new implants and as generator replacements. Douglas Insights builds the 2025 figure for the Cardiac Resynchronization Therapy (CRT) Devices Market bottom-up: 236,400 systems x USD 13,180 average price = USD 3.12 billion, and a revenue CAGR of 3.62% carries it to USD 4.45 billion by 2035. A fresh catalyst arrived on 23 March 2026, when Medtronic won FDA approval to place its 4.7 French OmniaSecure defibrillation lead in the left bundle branch area. Readers comparing it with other implants can start from our cardiovascular devices hub; every figure follows the published research methodology.

Which CRT device type makes the money: CRT-D new implants, CRT-P new implants or generator replacements?

CRT-D new implants make the money, carrying 52.6% of 2025 value, or USD 1.64 billion in our model, because a defibrillator-capable CRT system sells for roughly three to four times a CRT-P. Generator replacements hold 26.5% and CRT-P new implants 20.9%, across all hospital and outpatient implant settings.

CRT-D new implants reach USD 2.47 billion by 2035 at 4.17% a year, the fastest of the three. The reason is the new class of high-voltage devices that pace the conduction system: physicians who want both shock protection and physiological pacing now have approved hardware on both sides of the Atlantic.

CRT-P new implants are valued at USD 651.2 million in Douglas Insights’ 2025 model and grow 2.27% a year to USD 815.1 million. Their share is smaller because older heart failure patients without a defibrillator indication buy a cheaper device, and some of them now receive left bundle branch area pacing from a standard pacemaker instead.

Generator replacements account for USD 825.7 million and rise 3.41% a year to USD 1.15 billion. A CRT battery is replaced, not recharged, so every cohort implanted five to eight years ago returns as a scheduled swap.

The study also splits demand by lead approach (Biventricular pacing, Conduction system pacing) and by end user (Hospitals, Cardiac centers, Ambulatory surgery centers), with country tables behind every regional figure.

Why are heart failure referrals behind rising CRT-D and CRT-P implant demand?

Implant volumes rise 2.90% a year in the base case, and four forces explain every point of that growth: ageing heart failure cohorts, conduction-system-capable high-voltage devices, under-penetrated Asian markets and better referral of women. Together they lift CRT system units in our model from 236,400 in 2025 to about 314,600 in 2035.

Ageing heart failure cohorts contribute 1.24 percentage points, the largest single share, because the CRT candidate pool widens as heart failure patients live longer. Germany already implants 261.4 devices per million people, so the volume that ageing adds in high-income systems shows up in the replacement and new-implant queues at once. High-income countries average 112.4 CRT implants per million, which means each additional cohort of older patients converts into implants at an observed rate rather than an assumed one.

Conduction-system-capable high-voltage hardware contributes 0.71 points. On 12 February 2026 BIOTRONIK launched the Acticor Sky and Rivacor Sky families, the first CE-approved high-voltage ICD and CRT-D devices for left bundle branch area pacing, with the first European commercial implant at University Hospital Frankfurt in an 87-year-old patient. Medtronic followed in the United States on 23 March 2026, when its OmniaSecure lead gained approval for left bundle branch placement after the LEADR LBBAP study showed 100% defibrillation success at implant and a 2.1% major complication rate at three months. Medtronic describes left bundle branch optimized cardiac resynchronization therapy (LOT-CRT) as one route for patients who need resynchronization, which keeps those cases inside the CRT-D count rather than leaking to plain pacemakers. Medtronic later cited a strong OmniaSecure US launch in its fourth-quarter fiscal 2026 results, an early sign that implanters are adopting the approach.

Under-penetrated Asian and middle-income markets add 0.58 points. Douglas Insights uses the ESC (European Society of Cardiology) Atlas, which records 13.4 CRT implants per million in middle-income countries against 70.2 across the ESC region, a ratio of roughly 5.2 to 1. The base is so low that closing even a small part of the gap moves thousands of units.

Better referral of women adds 0.37 points. In the BIOWOMEN trial of 474 patients, women made up 48.5% of the cohort and reached an 83.3% responder rate against 70.6% for men. Douglas Insights reckons that as guideline committees act on that evidence, referral of women with heart failure with reduced ejection fraction rises, and the 0.37 points reflect that shift alone. The four contributions add to 2.90 points, the full volume leg.

Which barriers hold back CRT implants in middle-income cardiology wards?

Three barriers would cut CRT device volume growth from 2.90% to 1.60% a year in the slower case, removing 1.30 points. They are substitution by conduction system pacing in CRT-P candidates, thin electrophysiology capacity outside high-income systems and lead-related complications that make referrers cautious.

Substitution removes 0.62 points in the slower case. Abbott’s ASCEND CSP trial for its AVEIR leadless conduction system pacemaker plans up to 414 patients across up to 70 sites; if leadless or single-chamber physiological pacing proves adequate for borderline resynchronization candidates, CRT-P new implants lose cases they would otherwise win.

Electrophysiology capacity removes 0.41 points. A CRT implant needs a catheter laboratory, coronary sinus cannulation skills and device follow-up clinics, and middle-income systems implanting 13.4 devices per million rarely have enough of all three.

Complications and lead burden remove 0.27 points. BIOTRONIK’s CRT-NEXT trial of 636 patients found three times fewer atrial-lead complications with its 2-lead CRT-DX system than with conventional 3-lead CRT-D, which shows how much complication risk still sits in the standard approach.

How much does a CRT-D system cost compared with a CRT-P system?

A complete CRT-D system costs roughly three to four times a CRT-P system, which is why the CRT devices market carries a blended average price of USD 13,180 per implant in 2025. Douglas Insights puts price bands at about USD 4,000 for a CRT-P in tender markets up to about USD 24,000 for a premium US CRT-D.

Hospital payments set the ceiling. Abbott’s 2025 Medicare CRT coding guide lists a hospital outpatient payment of USD 32,062 under APC 5232 for a CRT-D implant (codes 33249 with 33225) and USD 19,071 under APC 5224 for a CRT-P implant (33208 with 33225). Inpatient CRT-D cases pay USD 50,434 under MS-DRG 275 and USD 33,198 under MS-DRG 277, while CRT-P cases range from USD 24,207 under MS-DRG 242 to USD 12,879 under MS-DRG 244. Those payments cover the procedure as well as the device, so the realised CRT device price is a fraction of each figure.

European prices sit lower. NICE technology appraisal TA314 costed a complete CRT-P system at GBP 3,411 and a complete CRT-D system at GBP 12,293, against GBP 9,692 for an ICD, using average selling prices from 2011. Douglas Insights sets 2025 price bands as follows: CRT-D systems at USD 14,000 to USD 24,000 in North America and USD 11,000 to USD 16,000 in Western Europe; CRT-P systems at USD 4,000 to USD 8,500 worldwide. The blended price rises 0.70% a year to about USD 14,130 by 2035, as mix shifts toward CRT-D and conduction-system-capable hardware.

Which companies build CRT-D and CRT-P devices, and what sets each apart?

Medtronic leads CRT devices with an estimated 38.6% of 2025 value, and the top three suppliers hold about 83.1% between them, by Douglas Insights estimates anchored on disclosed rhythm-management revenues. Boston Scientific and Abbott follow, with BIOTRONIK, MicroPort CRM and Medico S.r.l. serving narrower CRT niches.

Medtronic’s position is built on breadth and on the first defibrillation lead approved for left bundle branch placement. Its Cardiac Rhythm and Heart Failure division reported fiscal 2026 revenue of USD 7.50 billion, up 17.4%, with management citing a strong OmniaSecure US launch.

Boston Scientific builds on the Resonate family of MR-conditional CRT-D systems; the company states that its HeartLogic diagnostic detects heart failure events several weeks in advance with 70% sensitivity, and that EnduraLife gives nearly twice the usable battery capacity of Medtronic ICDs.

Abbott reported Rhythm Management sales of USD 2.65 billion for 2025, up 10.9%, and Heart Failure sales of USD 1.45 billion, up 13.2%. Its CRT position rests on that installed rhythm base and on the AVEIR conduction system pacing programme.

BIOTRONIK, based in Berlin, stands out on lead count: its CRT-DX system delivers CRT-D therapy with two leads and cut implant time by 14% in the CRT-NEXT trial. MicroPort CRM, now consolidated into the Hong Kong-listed MicroPort CardioFlow Medtech, sells the CE-marked TALENTIA SonR CRT-D. Medico S.r.l., based near Padua, makes biventricular pacemakers and states that over 70,000 of its VDD systems have been implanted.

Where are CRT implant rates per million highest, and which region grows fastest?

North America leads with USD 1.30 billion, or 41.7% of 2025 value, because CRT-D share and US prices are highest there. Asia Pacific grows fastest at 5.62% a year, while Germany’s 261.4 implants per million mark the ceiling that most regions remain far below.

North America rises at 3.04% a year to USD 1.75 billion by 2035, driven by Medicare-funded heart failure patients and the early US launch of conduction-system-capable defibrillation leads.

Europe holds USD 978.3 million in our 2025 model and grows 2.66% a year to USD 1.27 billion. Implant rates already reach 211.5 per million in the Czech Republic and 191.6 in Poland, so Europe grows on replacements and price mix, not new patients.

Asia Pacific is valued at USD 601.3 million and reaches USD 1.04 billion by 2035. The 5.62% rate reflects a low base: middle-income countries implant 13.4 devices per million, and every new catheter laboratory adds CRT capacity.

Latin America accounts for USD 130.9 million and grows 4.37% a year to USD 200.8 million, led by private cardiology centres in the largest economies.

The Middle East and Africa is the wildcard at USD 106.0 million, growing 5.55% a year to USD 181.9 million. The ESC Atlas shows Tunisia at 0.3 implants per million, so a single national heart failure programme would change that region’s curve.

Can remote heart failure diagnostics in CRT-D generators change follow-up economics?

Remote diagnostics add value to roughly 52.6% of CRT devices market spending, the CRT-D new implant share, because premium generators now carry heart failure sensors. Boston Scientific’s HeartLogic reports 70% sensitivity for heart failure events weeks ahead, which helps hospitals justify a costlier CRT-D over a CRT-P.

Device clinics that run remote checks can follow more CRT patients per nurse. Readers tracking the virtual follow-up side should see our Telehealth Market report, where remote monitoring revenue is sized separately from the implant itself.

Are women with heart failure under-referred for CRT implants?

Women reached an 83.3% responder rate against 70.6% for men in the 474-patient BIOWOMEN trial of cardiac resynchronization therapy, yet investigators state they remain less likely to receive CRT devices in routine practice. Douglas Insights counts better referral of women as 0.37 points of annual volume growth to 2035.

BIOWOMEN enrolled 230 women and 244 men across 25 sites in 8 European countries and Israel. Women also gained 14.7 points of left ventricular ejection fraction (LVEF) at 12 months, against 11.5 for men, and carried a hazard ratio of 0.41 for death or heart failure hospitalization.

Do hospitals or ambulatory surgery centers perform most CRT generator swaps?

Hospitals perform most CRT devices work, including the bulk of the 26.5% of value that comes from generator replacements, because CRT-D swaps need defibrillation testing and lead checks. Ambulatory surgery centers remain a small channel for CRT-P replacements in the United States.

A generator swap reuses the existing leads, so it carries a lower price than a new CRT system and fewer complications. Douglas Insights expects CRT generator replacements to reach USD 1.15 billion by 2035 as the cohorts implanted in the late 2010s and 2020s reach battery depletion.

What if conduction system pacing replaces biventricular CRT leads by 2035?

The CRT devices market reaches USD 4.45 billion by 2035 in the base case; slower growth gives USD 3.73 billion and faster growth USD 5.30 billion. Conduction system pacing decides which path holds.

In the faster case, the 23 March 2026 OmniaSecure approval and BIOTRONIK’s CE-approved LBBAP defibrillators pull conduction system pacing into CRT-D rather than away from it, and hybrid LOT-CRT systems command a price premium. In the slower case, leadless physiological pacemakers win the CRT-P borderline cases. Volume is the swing factor: one extra point of annual unit growth adds about USD 452 million to the 2035 value. Our 3.62% revenue CAGR sits inside the published range of about 0.7% to 6.6% a year, below its midpoint, because we net out conduction system pacing substitution.

Which FDA, CE and Medicare rules govern CRT-D approval and payment?

CRT devices and their leads need FDA approval in the United States and CE marking in Europe, and US payment follows Medicare codes such as APC 5232 at USD 32,062 for a CRT-D implant. Each new lead indication, such as left bundle branch placement, needs its own approval.

The OmniaSecure decision shows how indications expand. The lead was already approved. The 2026 decision added left bundle branch area placement for adults and adolescents aged 12 and up. In Europe, BIOTRONIK’s Acticor Sky and Rivacor Sky families reached the market through CE approval before any US clearance. In England, NICE appraisal TA314 covers implantable cardioverter defibrillators and cardiac resynchronisation therapy for NHS heart failure patients, and its costings remain the public reference for device prices.

Douglas Exclusive: the CRT Implant-Gap Model

The CRT Implant-Gap Model is a Douglas Insights model built from 7 data points from the ESC Atlas. It uses four country rates (Germany 261.4, Czech Republic 211.5, Poland 191.6, Tunisia 0.3 per million) and three aggregate rates for the CRT devices market (high income 112.4, ESC region 70.2, middle income 13.4 per million). Each is compared with the ESC-region reference of 70.2 implants per million.

The model is a ratio ladder, not a count of units. It uses no regional population table. Germany runs 3.7 times above the reference, the Czech Republic 3.0 times and Poland 2.7 times, while high-income countries average 1.6 times. Middle-income systems at 13.4 per million sit 5.2 times below it, and Tunisia at 0.3 sits about 234 times below. The model also flags data age: Germany reports 2023, the Czech Republic 2020 and Tunisia 2018, so 3 of the 4 named countries report data older than 2024 and their rates lag current practice.

For buyers of adjacent cardiovascular hardware, the same ratio logic underpins our Robotic Angiography System Market and Vascular Grafts Market studies.

What methodology converts 236,400 CRT implants into a dollar value?

The CRT devices market model multiplies 236,400 systems by USD 13,180 to reach USD 3.12 billion. Units then grow 2.90% and price 0.70% a year to USD 4.45 billion by 2035. Regional and segment builds were run separately and reconcile to that total.

The inputs are ESC Atlas implant rates, 2025 Medicare and NICE payment figures, company revenue and product disclosures, and Douglas Insights unit and price assumptions. Regional values sum to USD 3.12 billion in 2025 and USD 4.45 billion in 2035. Segment 2035 values sum to USD 4.44 billion, within 0.3% of the top-down figure. As a cross-check, the top three suppliers’ estimated CRT revenue of about USD 2.59 billion equals 83.1% of the market, consistent with Abbott’s USD 2.65 billion Rhythm Management line covering pacemakers and ICDs as well as CRT.

Sources

1. European Society of Cardiology, ESC Atlas CRT-D and CRT-P implantations per million (2025)
2. Medtronic OmniaSecure lead FDA approval for conduction system pacing (2026)
3. BIOTRONIK Acticor Sky and Rivacor Sky launch (2026)
4. Abbott Fourth quarter and full year 2025 results (2026)
5. Abbott 2025 Medicare CRT coding and payment guide (2025)
6. NICE TA314 implantable cardioverter defibrillators and cardiac resynchronisation therapy (2014)
7. Medtronic Fiscal 2026 fourth quarter results (2026)